Novavax (NASDAQ:NVAX – Get Rating) and JATT Acquisition (NYSE:JATT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, profitability, risk, analyst recommendations and dividends.
Profitability
This table compares Novavax and JATT Acquisition's net margins, return on equity and return on assets.
Get Novavax alerts:| Net Margins | Return on Equity | Return on Assets | |
| Novavax | -114.32% | -572.54% | -55.69% |
| JATT Acquisition | N/A | -105.35% | 6.64% |
Insider & Institutional Ownership
42.6% of Novavax shares are held by institutional investors. Comparatively, 44.8% of JATT Acquisition shares are held by institutional investors. 2.1% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Novavax and JATT Acquisition's top-line revenue, earnings per share (EPS) and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Novavax | $1.15 billion | 1.46 | -$1.74 billion | ($19.46) | -1.10 |
| JATT Acquisition | N/A | N/A | $6.85 million | N/A | N/A |
JATT Acquisition has lower revenue, but higher earnings than Novavax.
Analyst Ratings
This is a breakdown of recent recommendations for Novavax and JATT Acquisition, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Novavax | 2 | 0 | 5 | 0 | 2.43 |
| JATT Acquisition | 0 | 0 | 0 | 0 | N/A |
Novavax currently has a consensus price target of $128.25, indicating a potential upside of 497.07%. Given Novavax's higher possible upside, equities research analysts clearly believe Novavax is more favorable than JATT Acquisition.
Summary
JATT Acquisition beats Novavax on 5 of the 9 factors compared between the two stocks.
About Novavax
(Get Rating)
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
About JATT Acquisition
(Get Rating)
JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.
Receive News & Ratings for Novavax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novavax and related companies with MarketBeat.com's FREE daily email newsletter.